A 1-Year Pilot Study of Vagus Nerve Stimulation in Treatment-Resistant Rapid-Cycling Bipolar Disorder
J Clin Psychiatry 2008;69(2):183-189
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: Vagus nerve stimulation (VNS) appears to be
an effective treatment option for patients with treatment-resistant unipolar
and bipolar depression. The aim of the present study was to investigate the
efficacy of VNS in a group of patients with treatment-resistant rapid-cycling
bipolar disorder (RCBD) who were excluded from previous trials.
Method: Nine outpatients with a DSM-IV-TR diagnosis of
treatment-resistant RCBD were treated for 40 weeks with open-label VNS. The
first patient was enrolled in June 2001, and the last patient completed the
study in July 2005. Patients recorded their depression and mania mood symptoms
on a daily basis throughout the study using the National Institute of Mental
Health prospective life charting methodology and daily mood ratings. Patients
were assessed every 2 weeks during the 2-month baseline period before device
activation, every 2 weeks for the remaining 40 weeks of the study, and at the
end of the study with the 24-item Hamilton Rating Scale for Depression
(HAM-D-24), the 10-item Montgomery-Asberg Depression Rating Scale (MADRS), the
Young Mania Rating Scale (YMRS), the Clinical Global Impressions (CGI) scale,
the Global Assessment of Functioning (GAF) scale, and the 30-item Inventory of
Depressive Symptomatology Self-Report (IDS-SR-30). Any adverse events or device
complications were also recorded at each visit. The prospective life charts
were analyzed by calculating the area under the curve. Statistical analysis was
performed with a mixed-model repeated-measures regression analysis for repeated
measures of the various rating scales. Significant p values were <= .05.
Results: Over the 12-month study period, VNS was associated
with a 38.1% mean improvement in overall illness as compared to baseline (p =
.012), as well as significant reductions in symptoms as measured by the
HAM-D-24 (p = .043), MADRS (p = .003), CGI (p = .013), and GAF (p < .001)
rating scales. Common adverse events were voice alteration during stimulation
Conclusion: These data suggest that VNS may be an
efficacious and well-tolerated treatment option for patients with
treatment-resistant RCBD. Currently, no comparison is available in the
literature. Larger randomized trials are needed to verify these findings.